Injesta Oxi 12.5% injection 1 ml. #5

Injesta Oxi 12.5% injection 1 ml. #5

$34.00

Manufactured in: Ukraine

Injesta Oxi 12.5% injection 1 ml. #5 is used to treat respiratory disorders, heart conditions, high blood pressure, and edema through injection administration following instructions for safe use.

SKU: MED5538 Category:

Description

Injesta Oxi 12.5% Ampoules 1 ml. #5

Injesta® Oxy is an injectable solution used for treating various gynecological conditions, particularly those related to insufficient progesterone. The medicine contains hydroxyprogesterone caproate as its active ingredient, with each 1 ml of solution providing 125 mg of hydroxyprogesterone. The solution is available in ampoules and must be administered under the guidance of a healthcare professional.

Composition

Each 1 ml of Injesta® Oxy contains:

  • Hydroxyprogesterone caproate: 125 mg
  • Other ingredients: Benzyl benzoate, Ethyloleate

Dosage Form

Solution for injection.

Physical and Chemical Properties

Injesta® Oxy is an oily liquid, light green or light yellow in color, with a characteristic odor.

Pharmacotherapeutic Group

Sex hormones and modulators of the genital system. Progesterones. ATC code: G03DA03.

Pharmacological Properties

Pharmacodynamics

Injesta® Oxy is a synthetic analog of the corpus luteum hormone. It induces the transformation of the uterine lining from the proliferative to the secretory phase, facilitating normal implantation and supporting the fertilized egg’s development. The medicine also reduces the excitability and contractility of the uterine and fallopian tube muscles, thus helping to maintain pregnancy. It stimulates the development of breast glandular tissue and modulates the secretion of gonadotropins depending on the dosage. It also inhibits aldosterone’s effect, leading to increased excretion of sodium and chloride in the urine. The drug has catabolic and immunosuppressive properties. Injesta® Oxy provides a prolonged progestogenic effect, with action lasting between 8 to 14 days after a single intramuscular injection.

Pharmacokinetics

After intramuscular injection, the drug is absorbed slowly. Therapeutic concentrations are maintained for 7-14 days.

Indications

Injesta® Oxy is indicated for treating conditions caused by luteal insufficiency, such as:

  • Threatened miscarriage
  • Primary and secondary amenorrhea
  • Polymenorrhea
  • Dysfunctional uterine bleeding
  • Endometrial hyperplasia and endometriosis

Contraindications

Injesta® Oxy is contraindicated in patients with:

  • Hypersensitivity to the components
  • Ectopic or missed pregnancy in history
  • Vaginal bleeding of unknown origin
  • Liver dysfunction or diseases (hepatitis, cirrhosis)
  • Cholestatic jaundice in pregnancy
  • Kidney failure, porphyria
  • Malignant tumors of the breast or genital organs
  • Venous or arterial thromboembolism
  • Severe thrombophlebitis

Drug Interactions

Hydroxyprogesterone caproate may reduce the effect of drugs stimulating uterine muscle contractions, such as oxytocin, and enhance the effect of diuretics, antihypertensives, and immunosuppressants. It may reduce the effectiveness of anticoagulants and modify the effects of hypoglycemic agents. Concomitant use of β-adrenergic agonists and Injesta® Oxy can help reduce the side effects of β-adrenergic drugs. Injesta® Oxy also inhibits the metabolism of cyclosporine, increasing its concentration and toxicity risk.

Special Warnings

Injesta® Oxy should be used with caution in patients with cardiovascular disease, hypertension, diabetes, asthma, epilepsy, or depression. Patients with mental health disorders should be closely monitored, and treatment should be discontinued if signs of depression emerge. Blood glucose levels should be regularly monitored in diabetic patients. The drug should not be used in patients with unexplained vaginal bleeding or a history of peripheral artery disease. If signs of thromboembolism appear, therapy should be discontinued immediately.

Use During Pregnancy and Lactation

Injesta® Oxy should only be used in the first trimester of pregnancy to prevent miscarriage. Progesterone passes into breast milk, so the drug should not be used during breastfeeding.

Ability to Drive and Use Machines

Injesta® Oxy may cause vision disturbances and fatigue, so patients should avoid driving or operating machinery during treatment.

Dosage and Administration

Injesta® Oxy is administered intramuscularly to adult women. For preventing miscarriage, 125-250 mg (1-2 ml of the 12.5% solution) is injected once a week. The drug should only be used in the first trimester of pregnancy. For amenorrhea, 250 mg is injected once or in two doses after stopping estrogen therapy. To normalize the menstrual cycle in polymenorrhea or uterine bleeding, 62.5-125 mg is injected on days 20-22 of the cycle.

Overdose

An overdose of Injesta® Oxy may lead to increased side effects. Treatment should be discontinued, and symptoms managed as needed.

Side Effects

Possible side effects include:

  • Cardiovascular issues: hypertension, tachycardia, shortness of breath, venous thromboembolism
  • Metabolic issues: edema, fluid retention, glucose intolerance
  • Digestive issues: changes in appetite, bloating, abdominal pain, constipation, liver dysfunction
  • Central nervous system: headache, dizziness, depression, fatigue
  • Endocrine: weight gain, breast tenderness, menstrual irregularities
  • Genital issues: uterine cramps, vaginal dryness, itching, infections
  • Allergic reactions: rash, itching, angioedema, urticaria

Shelf Life

2 years.

Related products